Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS).
Endothelial dysfunction
Endothelin-1
Myalgic encephalomyelitis/chronic fatigue syndrome
Post-COVID syndrome
Reactive hyperaemia index
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
22 03 2022
22 03 2022
Historique:
received:
18
01
2022
accepted:
08
03
2022
entrez:
23
3
2022
pubmed:
24
3
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Fatigue, exertion intolerance and post-exertional malaise are among the most frequent symptoms of Post-COVID Syndrome (PCS), with a subset of patients fulfilling criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). As SARS-CoV-2 infects endothelial cells, causing endotheliitis and damaging the endothelium, we investigated endothelial dysfunction (ED) and endothelial biomarkers in patients with PCS. We studied the endothelial function in 30 PCS patients with persistent fatigue and exertion intolerance as well as in 15 age- and sex matched seronegative healthy controls (HCs). 14 patients fulfilled the diagnostic criteria for ME/CFS. The other patients were considered to have PCS. Peripheral endothelial function was assessed by the reactive hyperaemia index (RHI) using peripheral arterial tonometry (PAT) in patients and HCs. In a larger cohort of patients and HCs, including post-COVID reconvalescents (PCHCs), Endothelin-1 (ET-1), Angiopoietin-2 (Ang-2), Endocan (ESM-1), IL-8, Angiotensin-Converting Enzyme (ACE) and ACE2 were analysed as endothelial biomarkers. Five of the 14 post-COVID ME/CFS patients and five of the 16 PCS patients showed ED defined by a diminished RHI (< 1.67), but none of HCs exhibited this finding. A paradoxical positive correlation of RHI with age, blood pressure and BMI was found in PCS but not ME/CFS patients. The ET-1 concentration was significantly elevated in both ME/CFS and PCS patients compared to HCs and PCHCs. The serum Ang-2 concentration was lower in both PCS patients and PCHCs compared to HCs. A subset of PCS patients display evidence for ED shown by a diminished RHI and altered endothelial biomarkers. Different associations of the RHI with clinical parameters as well as varying biomarker profiles may suggest distinct pathomechanisms among patient subgroups.
Sections du résumé
BACKGROUND
Fatigue, exertion intolerance and post-exertional malaise are among the most frequent symptoms of Post-COVID Syndrome (PCS), with a subset of patients fulfilling criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). As SARS-CoV-2 infects endothelial cells, causing endotheliitis and damaging the endothelium, we investigated endothelial dysfunction (ED) and endothelial biomarkers in patients with PCS.
METHODS
We studied the endothelial function in 30 PCS patients with persistent fatigue and exertion intolerance as well as in 15 age- and sex matched seronegative healthy controls (HCs). 14 patients fulfilled the diagnostic criteria for ME/CFS. The other patients were considered to have PCS. Peripheral endothelial function was assessed by the reactive hyperaemia index (RHI) using peripheral arterial tonometry (PAT) in patients and HCs. In a larger cohort of patients and HCs, including post-COVID reconvalescents (PCHCs), Endothelin-1 (ET-1), Angiopoietin-2 (Ang-2), Endocan (ESM-1), IL-8, Angiotensin-Converting Enzyme (ACE) and ACE2 were analysed as endothelial biomarkers.
RESULTS
Five of the 14 post-COVID ME/CFS patients and five of the 16 PCS patients showed ED defined by a diminished RHI (< 1.67), but none of HCs exhibited this finding. A paradoxical positive correlation of RHI with age, blood pressure and BMI was found in PCS but not ME/CFS patients. The ET-1 concentration was significantly elevated in both ME/CFS and PCS patients compared to HCs and PCHCs. The serum Ang-2 concentration was lower in both PCS patients and PCHCs compared to HCs.
CONCLUSION
A subset of PCS patients display evidence for ED shown by a diminished RHI and altered endothelial biomarkers. Different associations of the RHI with clinical parameters as well as varying biomarker profiles may suggest distinct pathomechanisms among patient subgroups.
Identifiants
pubmed: 35317812
doi: 10.1186/s12967-022-03346-2
pii: 10.1186/s12967-022-03346-2
pmc: PMC8938726
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
138Informations de copyright
© 2022. The Author(s).
Références
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Chest. 2022 Jan;161(1):54-63
pubmed: 34389297
Int J Cardiol. 2012 Feb 9;154(3):335-6
pubmed: 22078396
Nat Rev Immunol. 2020 Jul;20(7):448
pubmed: 32499635
Nat Commun. 2021 Nov 12;12(1):6571
pubmed: 34772922
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Front Immunol. 2012 Aug 17;3:266
pubmed: 22912641
J Transl Med. 2021 Nov 22;19(1):471
pubmed: 34809664
J Hum Behav Soc Environ. 2015;25(6):657-674
pubmed: 27047234
Front Pediatr. 2019 Feb 05;7:12
pubmed: 30805319
Diabetologia. 2012 Mar;55(3):600-7
pubmed: 22200728
Eur Respir J. 2020 Jul 30;56(1):
pubmed: 32554538
Int J Biol Sci. 2013 Sep 23;9(9):966-79
pubmed: 24155670
Clin Diagn Lab Immunol. 2003 Jul;10(4):558-63
pubmed: 12853386
Front Immunol. 2021 Jan 08;11:602395
pubmed: 33488599
Occup Med (Lond). 2015 Jan;65(1):86
pubmed: 25559796
J Hypertens. 2020 Sep;38(9):1682-1698
pubmed: 32649623
Biomedicines. 2021 Jul 06;9(7):
pubmed: 34356845
FEBS Lett. 2007 Feb 20;581(4):673-80
pubmed: 17258205
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Geriatr Cardiol. 2020 May;17(5):264-269
pubmed: 32547609
Hypertension. 2019 Dec;74(6):1232-1265
pubmed: 31679425
Nat Rev Nephrol. 2021 Jan;17(1):46-64
pubmed: 33077917
J Vet Intern Med. 2019 Mar;33(2):363-382
pubmed: 30806496
ESC Heart Fail. 2020 Jun;7(3):1064-1071
pubmed: 32154656
Elife. 2021 Mar 23;10:
pubmed: 33752798
J Clin Med Res. 2020 May;12(5):293-299
pubmed: 32489504
Int J Cardiol. 2021 Dec 15;345:153-155
pubmed: 34706286
Adv Clin Chem. 2017;82:47-70
pubmed: 28939213
Brain Behav Immun. 2022 Mar;101:93-135
pubmed: 34973396
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Clin Respir J. 2018 Jan;12(1):84-90
pubmed: 27116287
J Pediatr Gastroenterol Nutr. 2019 May;68(5):662-668
pubmed: 30601366
Curr Vasc Pharmacol. 2012 Jan;10(1):4-18
pubmed: 22112350
Diagnostics (Basel). 2018 Sep 11;8(3):
pubmed: 30208578
Life (Basel). 2021 Sep 20;11(9):
pubmed: 34575135
Autoimmun Rev. 2020 Jun;19(6):102527
pubmed: 32247028
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34263741
Front Cardiovasc Med. 2021 Nov 30;8:745758
pubmed: 34917659
Clin Chem. 2000 Sep;46(9):1387-94
pubmed: 10973870
Ann Hematol. 2020 Aug;99(8):1701-1707
pubmed: 32583086
Front Med (Lausanne). 2021 Mar 22;8:642710
pubmed: 33829023
Angiogenesis. 2020 Nov;23(4):611-620
pubmed: 32458111
Autoimmun Rev. 2018 Jun;17(6):601-609
pubmed: 29635081
Clin Rheumatol. 2017 Sep;36(9):2071-2077
pubmed: 28074304
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Adv Ther. 2015 Oct;32(10):962-70
pubmed: 26525390